, but no significant improvement in SPL and PANSS negative score (p=0.12 and p=0.5). There were no correlations between neither of the QLS scores and any psychopathology scores at follow up. Likewise, there was no correlation between change in QLS scores and change in psychopathology. However, there was a negative correlation with change in SPL and medication dose (p=0.009) Discussion: In this study, we found that antipsychotic naïve patients with most severe symptoms had the lowest self-reported QLS. This relation was only observed for negative and general symptoms, but not for positive symptoms or GAF score. As expected there was a treatment induced improvement in positive and general symptoms as well as GAF score. Likewise, patients improved on QLS, but only on SR and not in the overall measure of SPL. This may partly be because antipsychotic medication primarily improves positive symptoms, which were not correlated with QLS. Additionally, there was even a negative correlation with medication dose, indicating that patients with higher doses had the least improvement I SPL score. The results indicate that there is not a simple relationship between antipsycotic induced improvement in psychopathology and selfreported QLS. High doses of medication may even reduce QLS.
S251. QUALITY OF LIFE OF CHRONIC

University of Campinas
Background: In recent years the goal of the treatment of patients with schizophrenia has shifted from symptom remission to the improvement in health as a whole. In this context, concepts such as quality of life (QoL), social and occupational functioning gained interest. The aim of this study is to investigate changes in QoL of chronic schizophrenia patients in the long-term follow-up and their associations with symptoms and level of community functioning. Methods: We will contact 85 patients with schizophrenia, considered clinically stable in the previous year, who participated in a study about the deficit syndrome of schizophrenia in 2009/2010. Back then, they were recruited in two sites: an outpatient service of a university general hospital (49 patients) and a community-based service (36 patients). Patients will be assessed with the same instruments adopted in the first study: SAPS, SANS, Calgary Depression Scale and Quality of Life Scale (QLS), plus the Personal and Social Performance Scale (PSP), not used at baseline. We started recruitment by the patients originally treated in the outpatient clinic.
Results: Until now, of the 49 patients, 2 dropped out treatment, 8 had been transferred to other services, 5 refused to participate, 1 had the diagnostic changed to bipolar disorder and 3 had died precociously. Of the deaths, 1 was due to complications secondary to the use of clozapine, 1 due to suicide and 1 patient was murdered by another patient during a psychiatric hospitalization. Up to now, 20 patients completed reassessment, mean age at baseline was 36.9 ± 8.9 years, mean duration of mental illness was 16 ± 10.1 years, and 75% were men. They had in mean, 10.7 ± 3.3 years of education, only 4 had any work activity and 55% had a low socioeconomic position. Assessment interval was 6.9 years ± 0.5. Some demographic aspects slightly worsened: only 15% had an occupation at follow-up, and 60% fell in the lower socioeconomic position. Between assessments, 8 (40%) patients have had periods of noncompliance to medication, 5 had psychiatric hospitalizations, three of them involuntarily. At follow-up 70% of the patients were using clozapine and, despite that, some presented residual positive symptoms (SAPS 6.2 ± 4.8); Calgary mean score was low (2.2 ± 2.2) and, except for the patient who died, there was no new suicide attempts between assessments. Negative symptoms severity was moderate in general (mean SANS 14.8 ± 7.2). Patients as a group had no significant change in QLS scores (61.5 ± 28.2 versus 60.1 ± 28.2 at follow-up). However, 15% of patients had an improvement greater than 20% in their QLS scores, and 30% had a worsening of their scores greater than 20%. Baseline scores on SANS (p=0.005), SAPS (p=0.03) and number of hospitalizations (p=0.03) were negatively correlated with follow-up QLS scores; and years of schooling at baseline was positively correlated (p=0.2). Baseline QLS scores were strongly associated with current QLS scores, as well as with PSP scores (both with P <0.000) at follow-up. Regarding PSP outcomes, 50% of patients were classified in the 70-31 interval (disabilities of various degrees) and 25% were under 30, requiring intensive support.
Discussion:
The results presented are partial, obtained with a provisional small sample size. Nevertheless, they show some interesting trends as the possible existence of two patterns of outcome regarding QoL in chronic schizophrenia patients: of significant improvement and one of worsening. If those initial findings are to be confirmed, our next step will be to investigate characteristics associated to improvement or deterioration of QoL in spite of a relative stability of symptoms. That sort of information is of great relevance in the pursuit of recovery for schizophrenia patients. Background: Schizophrenia is associated with considerable health care resource utilisation (HCRU) and costs, yet little is known about the patterns of care and HRCU in patients with schizophrenia prior to diagnosis. To address this knowledge gap, we examined the HCRU of patients with and without schizophrenia over a 5-year pre-diagnosis period. Methods: This US-based retrospective study used claims data from the HealthCore Integrated Research Database to identify newly diagnosed patients with schizophrenia (ICD-9: 295.x, ICD-10: F20.x) aged 15-54 years at diagnosis. Patients with schizophrenia were compared with a demographically matched (1:4) non-schizophrenia cohort during the 0-12 months, >1-2, >2-3, >3-4 and >4-5 years prior to schizophrenia diagnosis. During the pre-diagnosis periods, both all-cause and behavioural health-related HCRU were described. Results: The schizophrenia and comparator cohorts included 6,732 and 26,928 patients, respectively. The most common types of schizophrenia were schizoaffective disorder (49%), paranoid (24%) and unspecified (19%). Patients were distributed across all major US regions (Northeast: 18%, Midwest: 27%, South: 29%, West: 27%). Average age at diagnosis was 32.8 years and most patients were male (57.4%). The percentage of patients with at least one all-cause inpatient hospitalisation in the 0-12 months prior to diagnosis was 32.7% for patients with schizophrenia versus 3.9% for comparators. Patients with schizophrenia had a greater mean number of all-cause physician office visits in all pr-diagnosis time periods versus comparators (schizophrenia: 4.5-5.5 visits, comparators: 3.1-3.2 visits). Behavioural health-related HCRU was also more substantial in patients with schizophrenia versus comparators across all time periods in terms of the mean number of visits to a psychiatrist (1.8-2.9 vs 0.1 visits, respectively) or a psychologist (1.0-1.2 vs 0.2 visits, respectively). The percentage of patients with claims for antipsychotic medication was also greater in the schizophrenia cohort vs comparators (21.8-56.6% vs 0.7-1.0% of patients, respectively). Discussion: For up to 5 years prior to diagnosis, patients with schizophrenia have higher all-cause and behavioural health-related HCRU, in addition to higher use of anti-psychotic medications, compared with matched comparators. In the schizophrenia cohort, HCRU increased in frequency closer to diagnosis, compared with matched comparators, whose HCRU remained relatively stable. This study improves our understanding of the characteristics of clinically high-risk patients who go on to develop schizophrenia, who have more frequent encounters with health care providers than comparators. These results also suggest that early identification and treatment of patients prior to schizophrenia diagnosis could be optimised and is warranted. 
S252. HEALTH CARE RESOURCE UTILISATION IS HIGHER IN PATIENTS PRIOR TO DIAGNOSIS
University of Gothenburg
Background: The person-centered care approach has been little tested in inpatient settings for persons with schizophrenia and similar psychoses. We developed a staff educational intervention, Person-Centered Psychosis Care (PCPC) tailored to our care setting (4 hospital wards for persons with psychoses, 43 beds). The intervention was co-created by professionals, patients, and researchers using a participatory approach. There was a focus on the patient's narrative, the creation of partnership between staff and patient, an agreement between staff and patient concerning care, and a bridging of inpatient and outpatient care and support. The present study aims to describe patient outcomes associated with PCPC. Methods: The study had a before and after design. Before the PCPC intervention started, questionnaire data was collected from 50 inpatients shortly before discharge. Post intervention data are currently under collection (anticipated n=50). The primary outcome measure is self-reported empowerment (Empowerment Scale, Range 0-112) and the secondary measure is consumer satisfaction (UKU-ConSat Rating Scale, converted to range between 11 and 77). Participants also complete questionnaires related to possible confounding variables such as overall health (EQ-5D), symptom burden (PANSS), and functional ability (GAF).
Results:
The participants (46% women) included in the pre-intervention sample had a mean age of 47.5 years (SD=14.5). The total mean empowerment score for the pre-intervention sample was 82.6 (SD=8.1) whereas the mean consumer satisfaction score was 51.5 (SD=12.9). There were no statistically significant gender differences regarding empowerment or consumer satisfaction. There were no significant correlations between age, any of the confounding variables, and empowerment and consumer satisfaction. We will present results from comparisons between the pre-and postintervention groups regarding empowerment and consumer satisfaction.
Discussion:
The before and after design has its limitations, but if the PCPC intervention proves beneficial, such a model could be tested with a cluster randomized study design.
